Review article: Anti-fibrotic agents for the treatment of Crohn's disease - Lessons learnt from other diseases

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 2, 2010, Pages 189-201

  Szabo H ^a   Fiorino, G ^a,b   Spinelli, A ^c   Rovida, S ^a   Repici, A ^a   Malesci, A C ^a,c   Danese, S ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ATORVASTATIN; AZATHIOPRINE; CERTOLIZUMAB PEGOL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DASATINIB; DECORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EUDRAGIT; GC 1008; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INFLIXIMAB; MATRIX METALLOPROTEINASE INHIBITOR; MESALAZINE; METELIMUMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NILOTINIB; PLACEBO; RECOMBINANT OSTEOGENIC PROTEIN 1; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; CROHN DISEASE; DILATATION; EMBASE; ENDOSCOPY; ENTERITIS; HUMAN; INTESTINAL FIBROSIS; KIDNEY DISEASE; MEDLINE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; FIBROSIS; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION;

EID: 72949107361     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04171.x     Document Type: Review

References (125)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007 448 : 427 434.
2. Rieder F, Fiocchi C. Intestinal fibrosis in IBD - a dynamic, multifactorial process. Nat Rev Gasroenterol Hepatol 2009 6 : 228 235.
3. Oikarinen AI, Vuorio EI, Zaragoza EJ, Palotie A, Mon-Li C, Uitto J. Modulation of collagen metabolism by glucocorticoids : Receptor-mediated effects of dexamethasone on collagen biosynthesis in chick embryo fibroblasts and chondrocytes. Biochem Pharmacol 1988 37 : 1451 1462.
4. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004 18 : 816 827.
5. Sabate JM, Ameziane N, Lamoril J, et al. The V249I polymorphism of the CX3CR1 gene is associated with fibrostenotic disease behaviour in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2008 20 : 748 755.
6. Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006 367 : 241 251.
7. Vaglio A, Palmisano A, Corradi D, Salvarani C, Buzio C. Retroperitoneal fibrosis: evolving concepts. Rheum Dis Clin N Am 2007 33 : 803 817.
8. Badea I, Taylor M, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology 2009 48 : 213 221.
9. Peikert T, Daniels CE, Beebe TJ, et al. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med 2008 102 : 1342 1348.
10. Rogliani P, Mura M, Porretta MA, Saltini C. New perspectives in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2008 2 : 75 93.
11. Graham MF, Willey A, Adams J, Diegelmann RF. Corticosteroids increase procollagen gene expression, synthesis, and secretion by human intestinal smooth muscle cells. Gastroenterology 1995 109 : 1454 1461.
12. Brooker J, Beckett C, Saunders B, et al. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn's strictures may improve the outcome: a retrospective case series. Endoscopy 2003 35 : 333 337.
13. East JE, Brooker JC, Rutter MD, Saunders BP. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures. Clin Gastroenterol Hepatol 2007 5 : 1065 1069.
14. Warnatz K, Keskin AG, Uhl M, et al. Immunosuppressive treatment of chronic periaortitis: aretrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005 64 : 828 833.
15. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004 23 : 306 309.
16. Blank N, Max R, Lorenz HM. The role of DMARDs in systemic sclerosis therapy. Rheumatology 2006 45 : 42 4.
17. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991 144 : 291 296.
18. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009 104 : 2089 2096.
19. Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn's Disease Strictures. Inflamm Bowel Dis 2004 10 : 55 60.
20. Sorrentino D, Terrosu G, Avellini C. Infliximab in Crohn's disease: a look at the (not so distant) future. Digest Liver Dis 2008 40 : S229 35.
21. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumour necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999 116 : 1029 1034.
22. Vasilopoulos S, Kugathasan S, Saeian K, et al. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease. Am J Gastroenterol 2000 95 : 2503.
23. Toy LS, Scherl EJ, Kornbluth A, et al. Complete Bowel obstruction following initial response to infliximab therapy for Crohn's disease: a series of a newly described complication. Gastroenterology 2000 118 (Suppl 2 A569.
24. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006 101 : 1030 1038.
25. Holtman MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis 2005 20 : 1 8.
26. Sorrentino D, Avellini C, Beltrami CA, Pasqual E, Zearo E. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 2006 21 : 276 281.
27. Sinha R., Murphy P, Hawker P, Sanders S, Rajesh A, Verma R. Role of MRI in Crohn's Disease. Clin Radiol 2009 64 : 341 352.
28. Di Sabatino A, Pender SLF, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumour necrosis factor antibodies. Gastroenterology 2007 133 : 137 149.
29. Di Sabatino A, Ciccocioppo R, Benazzato L, Sturniolo GC, Corazza GR. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment Pharmacol Ther 2004 19 : 1019 1024.
30. Swaminath A, Lichtiger S. Dilation of Colonic Strictures by Intralesional Injection of Infliximab in Patients with Crohn's Colitis. Inflamm Bowel Dis 2008 14 : 213 216.
31. Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC. Infliximab treatment for symptomatic Crohn's disease strictures. Aliment Pharmacol Ther 2009 29 : 279 285.
32. Knapp AB, Mirsky FJ, Dillon EH, Korelitz BI. Successful infliximab therapy for a duodenal stricture caused by Crohn's disease. Inflamm Bowel Dis 2005 11 : 1123 1125.
33. Sorrentino D, Terrosu G, Vadalà S, Avellini C. Fibrotic strictures and anti-TNF-α therapy in Crohn's disease. Digestion 2007 75 : 22 4.
34. Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: What have we learnt so far? Digestion 2008 77 : 38 47.
35. Bahcecioglu IH, Koca SS, Poyrazoglu OK, et al. Hepatoprotective Effect of Infliximab, an Anti-TNF-α Agent, on Carbon Tetrachloride-Induced Hepatic Fibrosis. Inflammation 2008 31 : 215 221.
36. Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007 25 : 23 8 Abstract)
37. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P. Infliximab treatment in patients with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008 75 : 346 349.
38. Denton CP, Engelhart M, Tvede N, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009 68 : 1433 1439.
39. Watts KL, Sampson EM, Schultz GS, Spiteri MA. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005 32 : 290 300.
40. Yata Y, Gotwals P, Koteliansky V, et al. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 2002 35 : 1022 1030.
41. Grygielko ET, Martin WM, Tweed C, et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005 313 : 943 951.
42. Varga J, Paschke B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatology 2009 5 : 200 206.
43. Di Mola FF, Friess H, Scheuren A, et al. Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. Ann Surg 1999 229 : 67 75.
44. Lutz M, Knaus P. Integration of the TGF-beta pathway into the cellular signalling network. Cell Signal 2002 14 : 977 988.
45. Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol 2004 25 : 513 517.
46. Stallmach A, Schuppan D, Riese HH, et al. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology 1992 102 : 1920 1929.
47. Ma C, Tarnuzzer RW, Chegini N. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor-beta1. Wound Repair Regen 1999 7 : 477 485.
48. McKaig BC, McWilliams D, Watson SA, et al. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003 162 : 1355 1360.
49. Di Sabatino A, Pender SLF, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-TNF antibodies. Gastroenterology 2007 133 : 137 149.
50. Mulsow JJ, Watson RW, Fitzpatrick JM, et al. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg 2005 242 : 880 887.
51. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor-β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007 56 : 323 333.
52. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophtalmol Vis Sci 2003 44 : 3394 3401.
53. Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS. Available at: http://clinicaltrials.gov/ct2/show/ NCT00464321 (accessed on 10 May 2009).
54. Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma. Available at: http://clinicaltrials.gov/ct2/show/NCT00356460 (accessed on 10 May 2009).
55. Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF). Available at: http://clinicaltrials.gov/ct2/show/NCT00125385 (accessed on 10 May 2009).
56. Munger JS, Huang X, Kawakatsu H, et al. The Integrin avb6 Binds and Activates Latent TGFβ1: a Mechanism for Regulating Pulmonary Inflammation and Fibrosis. Cell 1999 96 : 319 328.
57. Puthawala K, Hadjiangelis N, Jacoby SC, et al. Inhibition of Integrin avb6, an Activator of Latent Transforming Growth Factor-b, Prevents Radiation-induced Lung Fibrosis. Am J Respir Crit Care Med 2008 177 : 82 90.
58. Horan GS, Wood S, Ona V, et al. Partial Inhibition of Integrin avb6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation Am J. Respir Crit Care Med 2008 177 : 56 65.
59. Rahimi RA, Leof EB. TGF-beta signalling: a tale of two responses. J Cell Biochem 2007 102 : 593 608.
60. Ishida W, Mori Y, Lakos G, et al. Intracellular TGF-β Receptor Blockade Abrogates Smad-Dependent Fibroblast Activation In Vitro and In Vivo. J Invest Dermatol 2006 126 : 1733 1744.
61. Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 2005 16 : 68 78.
62. Liu J. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004 287 : F7 16.
63. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999 5 : 226 230. (Pubitemid 29068532)
64. Albanis E, Safadi R, Friedman SL. Treatment of hepatic fibrosis: almost there. Curr Gastroenterol Rep 2003 5 : 48 56.
65. Liu J. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006 69 : 213 217.
66. Sugimoto H, Yang C, LeBleu VS, et al. BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J 2007 21 : 256 264.
67. Boor P, Sebeková K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007 22 : 3391 3407.
68. Zeisberg M, Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008 23 : 1395 1398.
69. Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol. 2003 285 : F1060 7.
70. Murray LA, Hackett TL, Warner SM, et al. BMP-7 Does Not Protect against Bleomycin-Induced Lung or Skin Fibrosis. PLoS ONE 2008 3 : e4039.
71. Jahanyar J, Joyce DL, Southard RE, et al. Decorin-mediated transforming growth factor-beta inhibition ameliorates adverse cardiac remodelling. J Heart Lung Transplant 2007 26 : 34 40.
72. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004 114 : 1308 1316.
73. Distler J, Distler O. Novel treatment approaches to fibrosis in scleroderma. Rheum Dis Clin N Am 2008 34 : 145 159.
74. Bournia VKK, Vlachoyiannopoulos PG, et al. Recent Advances in the treatment of Systemic sclerosis. Clinic Rev Allerg Immunol. 2009 36 : 176 200.
75. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibro genesis in vivo. FASEB J 2005 19 : 1 11.
76. van Daele PLA, Dik WA, Thio HB, et al. Is Imatinib Mesylate a Promising Drug in Systemic Sclerosis? Arthritis Rheum 2008 58 : 2549 2552.
77. Varga JA, Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin N Am. 2008 34 : 115 143.
78. Distler JHW, Distler O. Intracellular tyrosine kinases as novel targets for antifibrotic therapy in systemic sclerosis. Rheumatology 2008 47 : v10 1.
79. Distler JHW, Distler O. Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology 2009 48 : 2 4.
80. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 2006 5 : 717 718.
81. Magro F, Costa C. Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2006 12 : 1087 1089.
82. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophisiologies. Am J Physiol Renal Physiol 2007 292 : F905 11.
83. Kim H, Oda T, López-Guisa J, et al. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2001 12 : 736 748.
84. Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006 21 : S84 7.
85. Elli L, Bergmini CM, Bardella MT, Schuppan D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 2009 41 : 541 550.
86. Li C, Yang CW, Park JH, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004 286 : F46 57.
87. Chen HC, Guh JY, Shin SJ, Lai YH. Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis 2002 160 : 141 146.
88. Nishimura M, Tanaka T, Yasuda T, et al. Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation. Kidney Int Suppl 1999 71 : S97 100.
89. Hartner A, Klankeb B, Cordasic N, et al. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate- salt hypertension. J Hypertens 2009 27 : 376 385.
90. Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor- is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 2004 287 : L1323 32.
91. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Expl Pharmacol Physiol 2005 32 : 697 701.
92. Prospective Evaluation of Proteinuria and Renal Function in Non-Diabetic Patients With Progressive Renal Disease (PLANET II). Available at: http://clinicaltrials.gov/ct2/show/study/NCT000296400 (accessed on 24 May 2009).
93. Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease (PLANET I). Available at: http://clinicaltrials.gov/ct2/show/study/NCT000296374 (accessed on 24 May 2009).
94. Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS ONE 2009 4 : e5263. [Epub ahead of print].
95. Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol 2008 155 : 1085 1092.
96. Cleland JG, Coletta AP, Nikitin NP, Clark AL. Clinical trials update from the American College of Cardiology: darbepoetin alpha, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail 2006 8 : 326 329.
97. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004 110 : 674 678.
98. Effect of Rosuvastatin on Left Ventricular Remodelling. Available at: http://clinicaltrials.gov/ct2/show/study/NCT00505154 (accessed on 24 May 2009).
99. Haydont V, Bourgier C, Pocard M, et al. Pravastatin Inhibits the Rho/CCN2/Extracellular Matrix Cascade in Human Fibrosis Explants and Improves Radiation-Induced Intestinal Fibrosis in Rats. Clin Cancer Res 2007 13 : 5331 5340.
100. Burke JP, Watson RWG, Murphy M, Docherty NG, Coffey JC, O'Connell PR. Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor β1-mediated activation of intestinal fibroblasts. Br J Surg 2009 96 : 541 551.
101. Okada H, Watanabe Y, Kikuta T, et al. Bradykinin Decreases Plasminogen Activator Inhibitor-1 Expression and Facilitates Matrix Degradation in the Renal Tubulointerstitium under Angiotensin-Converting Enzyme Blockade. J Am Soc Nephrol 2004 15 : 2404 2413.
102. Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008 12 : 939 962.
103. Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000 118 : 1149 1156.
104. Corey KE, Shah N, Misdraji J, et al. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 2009 29 : 748 753.
105. Moreno M, Bataller R. Cytokins and renin-angiotensin signaling in hepatic fibrosis. Clin Liver Dis 2008 12 : 825 852.
106. Kobori H, Nagaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007 59 : 251 287.
107. Graciano ML, Cavaglieri Rde C, Dellê H, et al. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 2004 15 : 805 815.
108. Danser AHJ, Schalekamp MADH. Is there a cardiac renin-aldosteron system? Heart 1996 76 (S3 28 32.
109. Bader M, Ganten D. Update on tissue-renin angiotensin systems. J Mol Med 2008 86 : 615 621.
110. Sakamoto I, Ito Y, Mizuno M, et al. Lymphatic vessels develop during tubulointerstitial fibrosis. Kidney Int 2009 75 : 828 838.
111. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009 136 : 585 595.
112. Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis. Available at: http://clinicaltrials.gov/ct2/show/study/NCT00514683 (accessed on 10 May 2009).
113. Cerquaglia C, Diaco M, Nucera G, et al. Pharmacological and clinical basis of treatment of familial Mediterranean fever with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy 2005 4 : 117 124.
114. Niel E, Schermann J. Colchicine today. Joint Bone Spine 2006 73 : 672 678.
115. Morgan T, Weiss D, Nemchausky B, et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebocontrolled clinical trial of patient survival. Gastroenterology 2005 128 : 882 890.
116. Rennard S, Bitterman P, Ozaki T, et al. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach of the fibrotic disorders. Am Rev Respir Dis 1988 137 : 181 185.
117. Peterson T, Isbrucker R, Hooper M. In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacology 1994 28 : 259 270.
118. Huang W, Sun H, Pan X, et al. Effects of colchicine on synthesis and excretion of cytokines and extracellular matrix by human renal fibroblasts. Zhonghua Er Ke Za Zhi 2004 42 : 524 528.
119. Entzian P, Schlaak M, Sitzer U, et al. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997 175 : 41 51.
120. Ben-Chetrit E, Levy M. Colchicine: 1998 Update. Semin Arthritis Rheum 1998 28 : 48 59.
121. Wolf G, Thasis F, stahl RA. Cyclosporine stimulates expression of transforming growth factor-β in renal cells. Transplantation 1995 60 : 237 241.
122. El Sakka AI, Bakircioglu ME, Bhatnagar RS, et al. The effects of colchicine on a Peyronie's-like condition in an animal model. J Urol 1999 161 : 1980 1983.
123. Disel U, Paydas S, Dogan A. Effect of Colchicine on Cyclosporine Nephrotoxicity, Reduction of TGF-Beta Overexpression, Apoptosis, and Oxidative Damage: an Experimental Animal Study. Transplant Proc 2004 36 : 1372 1376.
124. Swartz RD. Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approach to treatment. Am J Kid Dis 2009 54 : 546 553.
125. Ferguson MWJ, Duncan J, Bond J, et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 2009 373 : 1264 1274.